These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26593678)

  • 21. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
    Norman P
    Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nociceptor beta II, delta, and epsilon isoforms of PKC differentially mediate paclitaxel-induced spontaneous and evoked pain.
    He Y; Wang ZJ
    J Neurosci; 2015 Mar; 35(11):4614-25. PubMed ID: 25788678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of skin microvasculature angiogenesis, cell migration, and permeability by a specific inhibitor of PKCalpha.
    Bokhari SM; Zhou L; Karasek MA; Paturi SG; Chaudhuri V
    J Invest Dermatol; 2006 Feb; 126(2):460-7. PubMed ID: 16374459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
    Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
    Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical PKC isoforms in cancer.
    Martiny-Baron G; Fabbro D
    Pharmacol Res; 2007 Jun; 55(6):477-86. PubMed ID: 17548205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of WO2012003387, Gilead's ASK1 inhibitors.
    Norman P
    Expert Opin Ther Pat; 2012 Apr; 22(4):455-9. PubMed ID: 22439661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TBK1 inhibitors: a review of patent literature (2011 - 2014).
    Yu T; Yang Y; Yin DQ; Hong S; Son YJ; Kim JH; Cho JY
    Expert Opin Ther Pat; 2015; 25(12):1385-96. PubMed ID: 26293650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature.
    Giordanetto F; Karis D
    Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C.
    Das J; Pany S; Panchal S; Majhi A; Rahman GM
    Bioorg Med Chem; 2011 Nov; 19(21):6196-202. PubMed ID: 21975067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
    Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
    Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.
    Carpenter C; Sorenson RJ; Jin Y; Klossowski S; Cierpicki T; Gnegy M; Showalter HD
    Bioorg Med Chem; 2016 Nov; 24(21):5495-5504. PubMed ID: 27647375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of protein kinase C activation and the vascular complications of diabetes.
    Das Evcimen N; King GL
    Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Synthesis, and Biological Evaluation of 1-Benzyl-1H-pyrazole Derivatives as Receptor Interacting Protein 1 Kinase Inhibitors.
    Zou C; Xiong Y; Huang LY; Song CL; Wu XA; Li LL; Yang SY
    Chem Biol Drug Des; 2016 Apr; 87(4):569-74. PubMed ID: 26577270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dynamics approach to probe PKCβII-ligand interactions and influence of crystal water molecules on these interactions.
    Grewal BK; Bhat J; Sobhia ME
    Expert Opin Ther Targets; 2015 Jan; 19(1):13-23. PubMed ID: 25363346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The C1 domain-targeted isophthalate derivative HMI-1b11 promotes neurite outgrowth and GAP-43 expression through PKCα activation in SH-SY5Y cells.
    Talman V; Amadio M; Osera C; Sorvari S; Boije Af Gennäs G; Yli-Kauhaluoma J; Rossi D; Govoni S; Collina S; Ekokoski E; Tuominen RK; Pascale A
    Pharmacol Res; 2013 Jul; 73():44-54. PubMed ID: 23643828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
    Norman P
    Expert Opin Ther Pat; 2009 Aug; 19(8):1165-8. PubMed ID: 19505194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.